Edwards Lifesciences (EW) Free Cash Flow (2009 - 2026)

Edwards Lifesciences has reported Free Cash Flow for 18 years, with the latest figure at -$21.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 109.4% year-over-year to -$21.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 72.09% YoY), and the FY2025 full-year result was $1.3 billion, up 360.5% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$21.1 million, down from $353.5 million in the prior quarter.
• The five-year high for Free Cash Flow was $516.2 million in Q3 2025, with the low at -$177.3 million in Q4 2024.
• Average Free Cash Flow over 5 years is $189.4 million, with a median of $240.9 million recorded in 2025.
• Peak annual rise in Free Cash Flow reached 2100.7% in 2024, while the deepest fall reached 467.08% in 2024.
• Tracing EW's Free Cash Flow over 5 years: stood at $213.9 million in 2022, then plunged by 77.42% to $48.3 million in 2023, then slumped by 467.08% to -$177.3 million in 2024, then surged by 299.38% to $353.5 million in 2025, then plunged by 105.97% to -$21.1 million in 2026.
• The last three Free Cash Flow figures came in at -$21.1 million (Q1 2026), $353.5 million (Q4 2025), and $516.2 million (Q3 2025), per Business Quant data.

Peer Comparison